MA51658A - Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies - Google Patents
Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathiesInfo
- Publication number
- MA51658A MA51658A MA051658A MA51658A MA51658A MA 51658 A MA51658 A MA 51658A MA 051658 A MA051658 A MA 051658A MA 51658 A MA51658 A MA 51658A MA 51658 A MA51658 A MA 51658A
- Authority
- MA
- Morocco
- Prior art keywords
- synucleinopathies
- antagonist
- treatment
- association including
- association
- Prior art date
Links
- 208000032859 Synucleinopathies Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483555P | 2017-04-10 | 2017-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51658A true MA51658A (fr) | 2020-12-02 |
Family
ID=63792736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051658A MA51658A (fr) | 2017-04-10 | 2018-04-09 | Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11160809B2 (fr) |
| EP (2) | EP4461362A3 (fr) |
| JP (1) | JP7271437B2 (fr) |
| KR (1) | KR20200002899A (fr) |
| CN (1) | CN110730662A (fr) |
| AU (1) | AU2018251604B2 (fr) |
| BR (1) | BR112019021125A2 (fr) |
| CA (1) | CA3059418A1 (fr) |
| EA (1) | EA201992414A1 (fr) |
| ES (1) | ES2986644T3 (fr) |
| HU (1) | HUE068710T2 (fr) |
| IL (3) | IL312486B2 (fr) |
| MA (1) | MA51658A (fr) |
| MX (1) | MX394351B (fr) |
| TW (1) | TWI803488B (fr) |
| WO (1) | WO2018191160A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7158425B2 (ja) | 2017-06-30 | 2022-10-21 | チェイス セラピューティクス コーポレイション | Nk-1アンタゴニスト組成物およびうつ病の処置における使用法 |
| IL294408A (en) | 2019-12-31 | 2022-08-01 | Chase Therapeutics Corp | Kinases as biomarkers for neurodegenerative conditions |
| WO2022182658A1 (fr) * | 2021-02-23 | 2022-09-01 | Hoth Therapeutics, Inc. | Utilisation d'aprépitant pour le traitement de la maladie d'alzheimer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572485D1 (en) | 1984-12-22 | 1989-09-28 | Thomae Gmbh Dr K | Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs |
| DE9290063U1 (de) | 1991-05-31 | 1994-02-24 | Pfizer Inc., New York, N.Y. | Chinuclidin-Derivate |
| US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| DE4241013A1 (de) * | 1992-12-05 | 1994-06-09 | Boehringer Ingelheim Kg | Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| EP0942732B1 (fr) | 1996-12-02 | 2004-11-17 | MERCK SHARP & DOHME LTD. | Utilisation d'antagonistes du recepteur nk-1 dans le traitement des diskynesies |
| DE19830201A1 (de) | 1998-07-07 | 2000-01-13 | Boehringer Ingelheim Pharma | Mittel mit antidepressiver Wirkung |
| WO2000006162A1 (fr) * | 1998-07-27 | 2000-02-10 | Boehringer Ingelheim Pharma Kg | Agents a effet antidepresseur, comprenant du pramipexol et un autre antidepresseur |
| DE60045564D1 (de) | 1999-02-24 | 2011-03-03 | Hoffmann La Roche | 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten |
| GB9923748D0 (en) | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
| CA2415890C (fr) | 2000-07-14 | 2009-04-07 | F. Hoffmann-La Roche Ag | N-oxydes en tant que promedicaments de derives de 4-phenyl-pyridine, antagonistes du recepteur nk1 |
| GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
| DE60123661T2 (de) | 2000-12-14 | 2007-08-16 | F. Hoffmann-La Roche Ag | Selbstemulgierende lipidmatrix (selm) |
| PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
| GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
| GB0310881D0 (en) * | 2003-05-12 | 2003-06-18 | Merck Sharp & Dohme | Pharmaceutical formulation |
| AR047439A1 (es) | 2004-01-27 | 2006-01-18 | Merck & Co Inc | Antagonistas del receptor hidroisoindolina taquiquinina |
| LT1713504T (lt) | 2004-01-30 | 2017-09-11 | Zoetis Services Llc | Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms |
| US20120253047A1 (en) | 2004-03-19 | 2012-10-04 | Dipharma S.P.A. | Process for the preparation of (r)-pramipexole |
| WO2006094948A1 (fr) * | 2005-03-08 | 2006-09-14 | Janssen Pharmaceutica N.V. | Dérivés de diaza-spiro-[4.4]-nonane en tant qu'antagonistes de neurokinines (nk1) |
| DE602006020450D1 (de) | 2005-07-11 | 2011-04-14 | Merck Sharp & Dohme | Ykinin-rezeptorantagonisten |
| ES2334061T3 (es) | 2005-08-15 | 2010-03-04 | University Of Virginia Patent Foundation | Neurorrestauracion con pramipexol r(+). |
| US8518926B2 (en) * | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
| PL2026803T3 (pl) | 2006-05-16 | 2012-05-31 | Knopp Neurosciences Inc | Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania |
| CN101641096A (zh) * | 2006-12-14 | 2010-02-03 | 诺普神经科学股份有限公司 | (r)-普拉克索的组合物以及使用该组合物的方法 |
| AU2008224869A1 (en) | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
| US20080254117A1 (en) | 2007-04-10 | 2008-10-16 | Noel Cotton | Process for preparing pramipexole dihydrochloride tablets |
| GB0806652D0 (en) | 2008-04-11 | 2008-05-14 | Glaxo Group Ltd | Anhydrous crystal form of orvepitant maleate |
| CN102573475B (zh) | 2009-08-14 | 2016-01-20 | 欧科生医股份有限公司 | 神经激肽-1拮抗剂的静脉内制剂 |
| EP2722045B1 (fr) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions pour traiter les nausées et vomissements à médiation centrale |
| WO2012140604A1 (fr) | 2011-04-15 | 2012-10-18 | Sandoz Ag | Formulations stables de chlorhydrate de pramipexole |
| WO2012175434A1 (fr) | 2011-06-20 | 2012-12-27 | Glaxo Group Limited | Formulations pharmaceutiques comprenant du vestipitant |
| ES2750246T3 (es) | 2013-10-08 | 2020-03-25 | Innopharma Inc | Formulaciones liquidas orales de aprepitant |
| JP6741655B2 (ja) | 2014-09-19 | 2020-08-19 | ヘロン セラピューティクス, インコーポレイテッドHeron Therapeutics, Inc. | アプレピタントのエマルジョン製剤 |
| US9850267B2 (en) | 2015-06-03 | 2017-12-26 | Navinta, Llc | Crystalline fosaprepitant dicyclohexylamine salt and its preparation |
| NL2015865B1 (en) | 2015-11-27 | 2017-06-13 | Le Vet B V | Maropitant Formulation. |
| JP7158425B2 (ja) * | 2017-06-30 | 2022-10-21 | チェイス セラピューティクス コーポレイション | Nk-1アンタゴニスト組成物およびうつ病の処置における使用法 |
-
2018
- 2018-04-08 IL IL312486A patent/IL312486B2/en unknown
- 2018-04-09 US US16/604,468 patent/US11160809B2/en active Active
- 2018-04-09 IL IL309770A patent/IL309770B2/en unknown
- 2018-04-09 CA CA3059418A patent/CA3059418A1/fr active Pending
- 2018-04-09 AU AU2018251604A patent/AU2018251604B2/en active Active
- 2018-04-09 JP JP2019555469A patent/JP7271437B2/ja active Active
- 2018-04-09 WO PCT/US2018/026699 patent/WO2018191160A1/fr not_active Ceased
- 2018-04-09 MA MA051658A patent/MA51658A/fr unknown
- 2018-04-09 KR KR1020197033121A patent/KR20200002899A/ko not_active Withdrawn
- 2018-04-09 EP EP24189957.4A patent/EP4461362A3/fr active Pending
- 2018-04-09 CN CN201880036987.9A patent/CN110730662A/zh active Pending
- 2018-04-09 EP EP18785191.0A patent/EP3609495B1/fr active Active
- 2018-04-09 MX MX2019012088A patent/MX394351B/es unknown
- 2018-04-09 EA EA201992414A patent/EA201992414A1/ru unknown
- 2018-04-09 BR BR112019021125-0A patent/BR112019021125A2/pt not_active Application Discontinuation
- 2018-04-09 HU HUE18785191A patent/HUE068710T2/hu unknown
- 2018-04-09 ES ES18785191T patent/ES2986644T3/es active Active
- 2018-04-09 IL IL269875A patent/IL269875B2/en unknown
- 2018-04-10 TW TW107112324A patent/TWI803488B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3609495C0 (fr) | 2024-07-24 |
| IL309770B1 (en) | 2024-10-01 |
| CA3059418A1 (fr) | 2018-10-18 |
| BR112019021125A2 (pt) | 2020-05-12 |
| IL269875B2 (en) | 2024-06-01 |
| IL312486B2 (en) | 2025-05-01 |
| IL309770A (en) | 2024-02-01 |
| CN110730662A (zh) | 2020-01-24 |
| WO2018191160A1 (fr) | 2018-10-18 |
| KR20200002899A (ko) | 2020-01-08 |
| IL269875A (fr) | 2019-12-31 |
| IL312486A (en) | 2024-07-01 |
| HUE068710T2 (hu) | 2025-01-28 |
| ES2986644T3 (es) | 2024-11-12 |
| AU2018251604B2 (en) | 2022-04-14 |
| IL269875B1 (en) | 2024-02-01 |
| EP3609495A4 (fr) | 2020-12-02 |
| AU2018251604A1 (en) | 2019-11-21 |
| IL312486B1 (en) | 2025-01-01 |
| JP2020516625A (ja) | 2020-06-11 |
| EA201992414A1 (ru) | 2020-03-16 |
| US11160809B2 (en) | 2021-11-02 |
| EP3609495A1 (fr) | 2020-02-19 |
| MX2019012088A (es) | 2020-02-07 |
| TW201841634A (zh) | 2018-12-01 |
| IL309770B2 (en) | 2025-02-01 |
| EP4461362A3 (fr) | 2025-02-19 |
| US20200147097A1 (en) | 2020-05-14 |
| TWI803488B (zh) | 2023-06-01 |
| EP3609495B1 (fr) | 2024-07-24 |
| EP4461362A2 (fr) | 2024-11-13 |
| MX394351B (es) | 2025-03-24 |
| JP7271437B2 (ja) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3766431A4 (fr) | Dispositif médical et méthode de traitement | |
| EP3380121A4 (fr) | Méthode de traitement de troubles oculaires | |
| MA46098A (fr) | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r | |
| EP3779023A4 (fr) | Appareil de traitement de vêtements | |
| EP3706737A4 (fr) | Inhibiteurs de ash1l et méthodes de traitement comprenant ces derniers | |
| EP3778649A4 (fr) | Méthode et composition de traitement de tumeurs | |
| EP3390634A4 (fr) | Compositions et méthodes pour le traitement de maladies oculaires | |
| EP3832007A4 (fr) | Appareil de traitement de vêtements | |
| EP3522934A4 (fr) | Compositions et méthode pour le traitement de la rénopathie | |
| EP3427678A4 (fr) | Dispositif médical et méthode de traitement | |
| EP3820461A4 (fr) | Méthode de traitement du cancer | |
| MA48730A (fr) | Compositions et méthodes de traitement de synucléinopathies | |
| EP3273955A4 (fr) | Traitement de maladies respiratoires | |
| EP3373962A4 (fr) | Compositions et méthodes de traitement de maladies auto-immunes et de cancers | |
| IL269363A (en) | Methods for measuring therapeutic effects of retinal disease therapies | |
| MA46061A (fr) | Traitement ascaroside de maladies auto-immunes et inflammatoires | |
| EA201791901A1 (ru) | Антагонисты рецептора нейрокинина-3 для терапевтического или косметологического лечения излишних жировых отложений на теле | |
| MA41462A (fr) | Méthode de traitement de maladies | |
| EP3331499A4 (fr) | Composition et méthode de traitement de troubles métaboliques | |
| EP3448365A4 (fr) | Méthode de traitement de la constipation | |
| EP3344258A4 (fr) | Traitement de maladies auto-immunes et de maladies auto-inflammatoires | |
| EP3316887A4 (fr) | Inhibiteurs de gls1 pour le traitement de maladies | |
| EP3933099A4 (fr) | Appareil de traitement de vêtements | |
| EP3976829A4 (fr) | Méthode de traitement ou de prophylaxie | |
| MA51658A (fr) | Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies |